Mercy Medical System first in New York to install clinical LumaGEM MBI system

Gamma Medica announced that New York’s first clinical LumaGEM Molecular Breast Imaging (MBI) system has been installed at Mercy Center, a member of Catholic Health Services of Long Island.

MBI is a secondary screening and diagnostic tool used for women who have dense breast tissue and those at risk of being diagnosed with cancer.

“We are thrilled to partner with the Mercy Medical Center to provide the women of New York access to state-of-the-art MBI technology,” said Philip Croxford, Gamma Medica president and CEO in a statement.

“This is just the latest milestone in Mercy’s longstanding dedication to the fight against cancer,” said Mercy’s Executive Vice President and Chief Administration Officer Ron Steimel.

According to a study published in the American Journal of Roentgenology, MBI increases early detection in women who are at high risk of being diagnosed with cancer, due to dense breast tissue. In the retrospective clinical study published, MBI was able to detect 7.7 cancers per 1,000 women screened that were not found using mammography. 

Jodelle joined TriMed Media Group in 2016 as a senior writer, focusing on content for Radiology Business and Health Imaging. After receiving her master's from DePaul University, she worked as a news reporter and communications specialist.

Around the web

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.